Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
10mon MSN
IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback